Mirati Therapeutics Inc. (MRTX) Sank To A New Low On Study Results

Mirati Therapeutics Inc. (MRTX) announced Sunday that 9 out of 11 NSCLC patients in its Phase 1b trial of Glesatinib experienced dose reductions and/or dose interruptions.

from RTT - Before the Bell http://ift.tt/1TThpnk
via IFTTT